Results 21 to 30 of about 1,054 (155)

Rimegepant for the treatment of migraine

Health Psychology Research, 2022
Migraine is a common form of primary headache, affecting up to 1 in every 6 Americans. The pathophysiology is an intricate interplay of genetic factors and environmental influence and is still being elucidated in ongoing studies. The trigeminovascular system is now known to have a significant role in the initiation of migraines, including the release ...
Berger, Amnon A, Winnick, Ariel, Carroll, Austin H, Welschmeyer, Alexandra, Li, Nathan, Colon, Marc, Paladini, Antonella, Ramírez, Giovanni F, Hasoon, Jamal, Cornett, Elyse M, Song, Jaehong, Varrassi, Giustino, Kaye, Adam M, Kaye, Alan D, Ganti, Latha   +14 more
openaire   +4 more sources

A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults

Cephalalgia Reports, 2021
Objective: This randomized, partially-blinded, placebo-controlled study evaluated hemodynamic effects, pharmacokinetic interactions, and safety of concomitant administration of oral rimegepant and subcutaneous sumatriptan.
Robert Croop, Andrea Ivans, Matt S Anderson, Joseph Stringfellow, Richard Bertz, Michael Hanna, Francine Healy, David A Stock, Vladimir Coric, Richard B Lipton   +9 more
doaj   +1 more source

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. [PDF]

Headache
Abstract Background Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety ...
Iannone LF, Silvestro M, Munafò A, Romozzi M, Geppetti P, Russo A.   +5 more
europepmc   +2 more sources

The efficacy of rimegepant for the acute treatment of vestibular migraine. [PDF]

Sci Rep
Abstract Introduction This study aimed to observe the efficacy and safety of rimegepant, a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of vestibular migraine (VM). Methods
Chu H, Pan J, Huang C.
europepmc   +4 more sources

Feasibility of administration of calcitonin gene-related peptide receptor antagonist on attenuation of pain and progression in osteoarthritis

Scientific Reports, 2023
Suppressing inflammation and abnormal subchondral bone turnover is essential for reducing osteoarthritis (OA) progression and pain relief. This study focused on calcitonin gene-related peptide (CGRP), which is involved in inflammation and bone metabolism,
Akinori Nekomoto, Tomoyuki Nakasa, Yasunari Ikuta, Chenyang Ding, Shigeru Miyaki, Nobuo Adachi   +5 more
doaj   +1 more source

New Gepants Against Acute Migraine A Systematic Review and Network Meta-Analysis

Amrita Journal of Medicine, 2021
Objectives: Recently two calcitonin gene-related peptide receptor antagonists (ubrogepant and rimegepant) were approved for the acute attack of migraine.
Dhyuti Gupta, Suryaprakash Dhaneria, Alok Singh   +2 more
doaj   +1 more source

Rimegepant in the Treatment of Migraine

Archives of Internal Medicine Research, 2020
Migraine is a common and chronic disorder with significant financial and socioeconomic burden. It is the 2nd most common reason for the years lived with disability after back pain. Current available treatment of migraine is limited to subpopulation due to poor tolerability, efficacy, side effects, contraindication and drug-drug interactions.
Muhammad Adnan Haider, Muhammad Hanif, Mukarram Jamat Ali, Muhammad Umer Ahmed, Sundas ,, Amin H Karim   +5 more
openaire   +1 more source

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine [PDF]

Journal of Managed Care & Specialty Pharmacy, 2020
DISCLOSURES: No funding supported the writing of this commentary. The authors have nothing to disclose.
Meg, Franklin, Eric, Druyts
openaire   +2 more sources

Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. [PDF]

Headache
Abstract Objective To evaluate changes in public interest in calcitonin gene‐related peptide therapies associated with major product lifecycle milestones using online search data from the United States and Europe. Background Calcitonin gene‐related peptide therapies have transformed migraine treatment, but the impact of key product lifecycle milestones
Ong B, Ahdab JE, Thompson N, Bhagat M, Ney J, Weathers AL.   +5 more
europepmc   +2 more sources

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

The Journal of Headache and Pain, 2022
Background The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg over 52-weeks.
Karissa Johnston, Linda Harris, Lauren Powell, Evan Popoff, Vladimir Coric, Gilbert L’Italien, Curtis P. Schreiber   +6 more
doaj   +1 more source